Twist Bioscience posted 19.3% revenue growth in fiscal Q2 2026 and raised full-year guidance, but it still faces losses and a demanding valuation. The stock earns a Hold as execution improves while investors wait for profitability.
Twist Bioscience (TWST) has a credible growth engine but a demanding valuation. Fiscal Q2 2026 revenue reached $110.7M, up 19.3% year over year, marking the company's 13th consecutive quarter of sequential revenue growth. DNA Synthesis and Protein Solutions grew 28% to $53.3M, while NGS Applications grew 12% to $57.4M. The business is gaining operating leverage, yet it still posted a $44.0M net loss and a $13.3M adjusted EBITDA loss in the quarter.
The investment case rests on three linked facts: a silicon-based DNA synthesis platform, rising demand from AI-enabled drug discovery and oncology diagnostics, and management's forecast for adjusted EBITDA breakeven in Q4 fiscal 2026. Fiscal 2026 revenue guidance was raised to $442M to $447M, with gross margin expected to remain above 52%.
The counterweight is valuation and execution. TWST trades at 13.8x enterprise value to revenue, has trailing EPS of -$1.32, and continues to consume cash. The latest quoted insider transaction in the supplied market record was at $93.89, close to the $92.50 analyst consensus target. A moderate-risk investor with a medium-term horizon is better served by a Hold than by chasing the growth narrative.
TWST manufactures synthetic DNA-based products for therapeutics, diagnostics, industrial biology, agriculture, data storage, and academic research. The company was incorporated in 2013, completed its IPO in 2018, and is headquartered in South San Francisco, California. It had 979 employees in the supplied corporate profile.
The company organizes its operating revenue around two broad categories: DNA Synthesis and Protein Solutions, and NGS Applications. The portfolio includes synthetic genes, gene fragments, oligo pools, DNA libraries, antibody discovery services, immunoglobulin G proteins, library preparation kits, human exome kits, custom panels, and methylation detection kits.
TWST's fiscal 2025 revenue was $376.6M, compared with $313.0M in fiscal 2024 and $245.1M in fiscal 2023. NGS Tools produced $208.1M in fiscal 2025, or 55.3% of revenue, while Synthetic Genes generated $113.6M, or 30.2%. The mix shows a substantial NGS base alongside faster-growing DNA synthesis and protein opportunities.
TWST's platform strategy is to capture more of the design-build-test-learn workflow. A customer can purchase a DNA fragment, a clonal gene, an oligo pool, an antibody-related product, or a more complete discovery service. That breadth gives the company more opportunities to expand wallet share, although it also places TWST in several competitive markets at once.
DNA Synthesis and Protein Solutions was the strongest reported segment in fiscal Q2 2026. Revenue rose to $53.3M from $41.6M a year earlier and increased 4% sequentially. Therapeutics revenue reached $40.8M, up 55% from $26.3M in the prior-year quarter. That performance reflects demand for synthetic DNA, protein expression, antibody discovery, and related data characterization.
NGS Applications generated $57.4M in fiscal Q2 2026, up 12% year over year and 9% sequentially. Management expects NGS to drive sequential growth in the second half of fiscal 2026 and return to 20% growth by Q4. That trajectory matters because NGS products support recurring consumable workflows rather than only project-based discovery work.
The fiscal 2025 segment data also show a gradual shift toward higher-value products. Antibody Discovery revenue rose to $23.5M from $20.3M in fiscal 2024, while Synthetic Genes increased to $113.6M from $92.7M. NGS Tools grew to $208.1M from $169.1M. The mix is still dominated by NGS, but the growth contribution from therapeutics and synthetic genes is becoming more important.
The segment structure gives TWST several shots at growth, but it also complicates the margin story. The company is investing in protein characterization, digital infrastructure, commercial capacity, and manufacturing automation while gross margin is just above 50%. The model needs revenue growth and process improvements to convert breadth into durable earnings.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
The flagship asset is TWST's silicon-based DNA writing platform. The technology miniaturizes and parallelizes chemical reactions, allowing the company to synthesize large numbers of DNA sequences on a silicon chip. Management identifies cost, scale, speed, automation, and precision as the platform's central advantages.
The platform supports synthetic genes up to 5,000 base pairs, according to company materials, and Express Genes with a five-business-day turnaround. TWST also uses the platform to produce oligo pools and DNA libraries containing large numbers of distinct sequences. In fiscal Q2 2026, the company shipped approximately 300,000 genes, compared with approximately 227,000 in the year-earlier quarter.
The product has value beyond the initial sequence order. A customer can begin with a pool library, select promising candidates, advance them into individual synthesis, express proteins, and use characterization data to refine the next design cycle. That workflow increases the revenue opportunity per research program and connects the DNA synthesis business to protein solutions.
TWST's strongest competitive advantage is the combination of proprietary manufacturing technology and a growing product portfolio. The silicon platform is not a single product. It feeds synthetic genes, oligo pools, DNA libraries, protein solutions, and selected NGS products. The same manufacturing base can therefore support several customer applications.
Production acceptance rates provide a concrete measure of progress. Management said TWST can manufacture approximately 98.5% of clonal genes and about 99% of DNA requests more broadly. It is targeting approximately 99.5% acceptance for clonal genes and 99.9% for broader DNA products. Higher acceptance rates can reduce the number of orders routed to competing suppliers.
Innovation is also appearing in commercial partnerships. Amazon Web Services selected TWST as a wet lab partner for Amazon BioDiscovery, an AI-powered drug discovery application. TWST also entered a bispecific licensing agreement with Invenra and launched the Twist TrueAmp Library Preparation Kit and Twist PCR-Free WGS Library Preparation Kit.
The moat is meaningful but not unassailable. TWST's 10-K identifies competition from companies with greater resources, broader intellectual property portfolios, longer operating histories, and more established distribution channels. The platform earns a premium only if it continues to deliver better speed, complexity handling, and workflow integration.
TWST's operating model depends on high-throughput manufacturing, software-enabled order intake, and specialized laboratory workflows. The company uses an algorithm in its e-commerce system to identify sequences that may be difficult to manufacture. That process links customer experience with production planning before an order enters the laboratory.
Fiscal Q2 2026 activity reached approximately 2,583 customers shipped to, up from 2,431 in the prior-year quarter. The company also reported 627 NGS Applications customers, including 174 that had adopted TWST products. These figures show operating scale, although the top 10 NGS customers still represented approximately 39% of NGS Applications revenue.
TWST is investing in manufacturing automation and capacity. Fiscal Q2 capital expenditures were approximately $8.0M, and the company said its newer facility supports further automation. Management expects incremental revenue to produce a 75% to 80% average drop-through to gross profit as workflows become more automated.
Supply chain execution is a central risk rather than a footnote. The 10-K identifies dependence on manufacturing capacity and key suppliers. A delay in equipment, reagents, facility expansion, or quality control would strike directly at the platform's key selling points: speed and reliable delivery.
TWST operates where synthetic biology, precision medicine, AI-enabled drug discovery, and next-generation sequencing intersect. MarketsandMarkets estimates the broader biotechnology industry at $546.0B in 2025, while Mordor Intelligence estimates a broader biotechnology market of $2.42T in 2026. The difference reflects market-definition scope, but both sources identify an expanding industry.
Synthetic biology is a faster-growing adjacent market. MarketsandMarkets estimates that market at $12.33B in 2024 and $31.52B in 2029, a 20.6% compound annual growth rate. TWST's exposure to synthetic genes, oligo pools, and DNA libraries gives it a direct position in that growth vector.
Oncology diagnostics is another important market. TWST highlighted minimal residual disease testing, tumor-informed panels, and high-sensitivity target enrichment. These workflows require accurate panel design, uniform coverage, and repeat consumable purchases. NGS Applications revenue of $57.4M in Q2 shows that this opportunity already has commercial scale inside TWST.
AI is expanding the number of sequences researchers want to test. Management said AI-enabled discovery has moved from a small number of accounts in 2025 to dozens of accounts. That increases the volume of DNA and antibody candidates that need synthesis and characterization, giving TWST a direct way to monetize the computational expansion of biological design.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
TWST serves a broad customer base across therapeutics, diagnostics, industry and applied research, academia, government, and global supply partners. In fiscal Q2 2026, therapeutics revenue was $40.8M and diagnostics revenue was $40.0M. Academic research and government contributed $12.8M, industry and applied markets contributed $5.8M, and global supply partners contributed $11.4M.
Therapeutics was the standout customer category, growing 55% year over year. Diagnostics grew 14%, while academic research and government grew 3%. Industry and applied revenue fell from $7.0M to $5.8M, and global supply partner revenue declined from $12.0M to $11.4M because of order timing.
Geographic exposure is concentrated in the Americas, which generated approximately $64.3M in Q2 revenue. EMEA produced $37.3M and APAC produced $9.1M, with APAC representing 8% of revenue. China represented approximately 1% of total revenue, limiting direct exposure to China-related demand shocks while leaving TWST exposed to broader cross-border supply and regulatory issues.
The customer mix supports resilience, but concentration remains relevant in NGS. The top 10 NGS customers accounted for approximately 39% of NGS Applications revenue. A large account can accelerate growth when it expands adoption, but a purchasing delay can also affect quarterly results.
TWST competes with Integrated DNA Technologies, part of Danaher (DHR), GeneArt from Thermo Fisher Scientific (TMO), GENEWIZ from Azenta (AZTA), Eurofins Genomics, GenScript, ATUM, Elegen, Ansa Biotechnologies, Telesis Bio, and OriGene in synthetic DNA. In NGS workflows, competitors include Illumina (ILMN), Roche, Agilent Technologies (A), New England Biolabs, and Watchmaker Genomics.
The competitive field divides into large diversified life-science companies and specialized providers. DHR, TMO, and ILMN bring deeper distribution, larger R&D budgets, and wider customer relationships. Specialized competitors can focus on a narrow application and compete aggressively on price, turnaround time, or construct complexity.
TWST's response is breadth. Management says customers prefer one partner across the workflow rather than stitching together several vendors. The company combines DNA synthesis, protein expression, antibody discovery, and NGS tools. That approach can increase switching costs as a research program moves from early design into validation and commercial testing.
The danger is that breadth can become an expensive collection of businesses if cross-selling fails. Fiscal Q2 operating expenses excluding cost of revenue and litigation settlement costs reached $95.8M, up from $87.6M. TWST must prove that commercial and digital investments produce enough gross profit to offset the cost of serving a wider workflow.
The 2026 EY biotechnology report describes an industry facing economic and geopolitical disruption, tighter financing, patent cliffs, and cost pressure. Those conditions are a direct test of TWST's value proposition. Customers with constrained budgets have a stronger reason to adopt tools that improve throughput and reduce cost per sequence, but they also have a stronger reason to delay discretionary research spending.
The macro backdrop favors automation and productivity. Gartner identifies AI, data-driven innovation, multiomics, cloud architecture, and cyber resilience as important life-science technology priorities. TWST's AWS BioDiscovery partnership and AI-enabled antibody work place the company within those investment themes.
Regulatory developments also support advanced biology. The FDA issued 2026 guidance on chemistry, manufacturing, and controls flexibilities for human cellular and gene therapy products. The EMA describes the new European pharmaceutical legislation as a major modernization of the regulatory system. These actions support innovation, although every new product still faces validation, quality, and compliance demands.
TWST's geographic data provide a useful geopolitical marker. APAC revenue grew 30% year over year to $9.1M, while China accounted for approximately 1% of total revenue. That modest China exposure reduces one direct risk, but global customers and suppliers still connect TWST to export controls, research restrictions, and cross-border logistics.
Cash and investments of $382.5M against $150.1M of debt leave Twist with a workable liquidity cushion, but the company still burned $26.6M of free cash flow in the quarter.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Revenue climbed 19.3% to $110.7M in fiscal Q2 2026, yet Twist still posted a $44.0M net loss and a $13.3M adjusted EBITDA loss as gross margin stayed just above 50%.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Management lifted fiscal 2026 revenue guidance to $442M-$447M and expects adjusted EBITDA breakeven in Q4 2026, with gross margin projected to remain above 52%.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →At 13.8x enterprise value to revenue and a trailing EPS of -$1.32, Twist trades at a premium that leaves limited room for disappointment.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →The latest analyst consensus target sits at $92.50, while the report's fair value view is $95 and the stock's recent insider transaction was at $93.89.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →TWST is building one of the more differentiated platforms in life-science tools. Its silicon-based DNA synthesis system supports high-throughput production, expanding product breadth, and a growing role in AI-enabled drug discovery and oncology diagnostics. Fiscal Q2 2026 results confirmed real commercial momentum, with revenue up 19.3%, therapeutics up 55%, and gross margin above 50%.
The stock is not yet a clean earnings compounder. The latest quarter produced a $44.0M net loss, free cash flow remained negative, and cash declined over the year. Management's Q4 fiscal 2026 adjusted EBITDA breakeven target is the next major test of whether revenue growth can finally translate into operating leverage.
For a moderate-risk investor, the appropriate stance is patience. The platform and market opportunity justify keeping TWST on the investment list, but the $95.00 fair-value estimate leaves little room for disappointment near the latest quoted reference price. A more attractive risk-reward balance begins at the $75.00 Buy level, while the strongest margin of safety appears at $55.00.
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.
Get Full Access →Not ready to subscribe? ·
Cancel anytime
Twist Bioscience Corporation (TWST) rose after a mixed quarter that featured an EPS miss but a revenue beat, continued sequential growth, and improving segment momentum. This deep dive examines the margin expansion, adjusted EBITDA breakeven path, and why investors focused on the bigger operating picture.
Twist Bioscience Corporation (TWST) rises after reporting earnings misses, with shares up 5.5% as investors react to the latest quarterly results.
Twist Bioscience Corporation (TWST) drops despite revenue growth and raised guidance, as a wider-than-expected EPS loss overshadowed strong segment momentum, margin improvement, and continued sequential sales gains. This deep-dive breaks down the earnings miss, operating trends, and why investors focused on profitability over the top-line beat.